MedicaidPrior AuthLow impact
Signifor® LAR (pasireotide) (Revised)
Humana·LA · Endocrinology·Medicaid
Effective date
Nov 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has revised prior authorization requirements for Signifor LAR (pasireotide), a specialty medication used to treat rare endocrine disorders including Cushing's Disease and acromegaly. The policy requires specific diagnostic criteria and documentation that surgery was inadequate or not an option before approval.
Action Required
Before November 1, 2025: Providers treating patients with Cushing's Disease or acromegaly must obtain prior authorization for Signifor LAR through Humana Medicaid Louisiana. Ensure documentation includes diagnosis confirmation, evidence of inadequate surgical response or surgical contraindication, and absence of severe hepatic impairment. Recommended pre-treatment testing includes fasting glucose, A1c, liver tests, ECG, and gallbladder ultrasound.